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ABSTRACT
Using microarray information from oro-pharyngeal data sets and results from 
primary human foreskin keratinocytes (HFK) expressing Human Papilloma Virus 
(HPV)-16 E6/E7 proteins, we show that p63 expression regulates signalling molecules 
which initiate cell migration such as Src and focal adhesion kinase (FAK) and induce 
invasion in 3D-organotypic rafts; a phenotype that can be reversed by depletion of 
p63. Knockdown of Src or FAK in the invasive cells restored focal adhesion protein 
paxillin at cell periphery and impaired the cell migration. In addition, specific inhibition 
of FAK (PF573228) or Src (dasatinib) activities mitigated invasion and attenuated the 
expression/activity of matrix metalloproteinase 14 (MMP14), a pivotal MMP in the 
MMP activation cascade. Expression of constitutively active Src in non-invasive HFK 
expressing E6/E7 proteins upregulated the activity of c-Jun and MMP14, and induced 
invasion in rafts. Depletion of Src, FAK or AKT in the invasive cells normalised the 
expression/activity of c-Jun and MMP14, thus implicating the Src-FAK/AKT/AP-1 
signalling in MMP14-mediated extra-cellular matrix remodelling. Up-regulation of Src, 
AP-1, MMP14 and p63 expression was confirmed in oro-pharyngeal cancer. Since p63 
transcriptionally regulated expression of many of the genes in this signalling pathway, 
it suggests that it has a central role in cancer progression.
INTRODUCTION
Cases of head and neck squamous cell carcinomas 
(HNSCC) are increasing globally by 600,000/annum. 
A significant proportion of HNSCC are oro-pharyngeal 
cancers and at least 25% of these cancers are associated 
with the Human Papilloma Virus (HPV) infection, in 
particular HPV-16, which also causes cervical cancer 
[1, 2]. Oro-pharyngeal cancer patients with HPV infection 
respond better to the available therapies than the HPV-
negative indicating a potential diversity in these cancers. 
The oncogenic transformation of HPV-positive tumours is 
believed to be triggered by integration of viral genome into 
the host chromosome, leading to upregulated expression 
of E6 and E7 proteins which are well known to degrade 
p53 and retinoblastoma proteins, respectively. The E6 and 
E7 proteins transcriptionally regulate many cellular genes 
including the p63 family, which are overexpressed in oro-
pharyngeal cancers [3, 4].
p63, a member of the p53 transcription factor 
family, is essential for development of stratified epithelium 
and limbs as inherited recessive mutations in the p63 gene 
cause cranial developmental problems with cleft palate, 
skin defects and hypoplasia of breasts in humans [5, 6]. 
Recent microarray studies have highlighted the oncogenic 
properties of certain p63 isoforms in inducing epithelial 
to mesenchymal transition, cell migration, extracellular 
matrix (ECM) remodelling and invasion [7–9].
Aberrant activities of proteins regulating cell 
motility can promote invasion. Genes from the non-
receptor tyrosine kinase family i.e. protein tyrosine kinase 
2 (PTK2; which encodes focal adhesion kinase (FAK)) 
and Src are known regulators of cell migration [10, 11]. 
Activation of FAK (Tyr576/577) and Src (Tyr416) are regulated 
by mutual phosphorylation events at the indicated 
amino acids near cell-matrix adhesion sites, leading 
to the formation of an activated Src-FAK complex. In 
addition, Src activity is also regulated by phosphorylation 
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of the C-terminal negative regulatory Tyr530 site, as 
point mutations or loss of C-terminal residues results 
in constitutively active Src, which is often seen in 
colon cancers patients [12, 13]. Studies with tumour 
tissue arrays have shown a direct correlation between 
activated Src-FAK complex and increase in tumour 
progression [14–16]. The activated Src-FAK complex is 
known to mediate the phosphorylation of scaffold proteins 
like paxillin at Tyr118 to trigger the disassembly of focal 
contacts, which is prerequisite for cell migration [17].
Cancer cells also secrete increased amounts of 
proteinases like matrix metalloproteinases (MMPs), which 
degrade different components of ECM and basement 
membrane to facilitate the invasion [18]. MMPs are zinc-
dependent endopeptidases which are activated through 
cleavage of their precursors either by proteases like 
plasmin or other active MMPs including collagenases 
(MMP1), gelatinases (MMP2, MMP9), stromelysins 
(MMP3) and membrane-type MMPs (MMP14). Most of 
these MMPs are overexpressed in most types of HNSCC 
and are linked with poor prognosis of the disease. Thus, 
the signalling pathways regulating the gene expression of 
these MMPs are critical in disease progression [19].
In the tumour microenvironment, the increased 
presence of inflammatory mediators stimulate the 
expression of MMPs through induction of either 
extracellular signal-regulated kinase (ERK), c-Jun NH
2
-
terminal kinase (JNK) or phosphoinositide 3-kinase/AKT 
signalling pathways [19]. We have previously shown that 
AKT, a serine/threonine kinase, regulates epithelial cell 
migration and invasion [20, 21]. Despite these findings, 
the underlying molecular mechanisms driving epithelial 
invasion after HPV16 infection still remains obscure, and 
is the focus of this study.
Here, we show that p63, Src, PTK2, c-Jun (activator 
protein-1 (AP-1) transcription factor) and MMP14 genes 
are upregulated in patients with oro-pharyngeal cancers. 
Using human foreskin keratinocytes (HFK) expressing 
HPV16 E6 and E7 genes (E6/E7-HFK) we show that 
increased expression of p63 promotes migration and 
invasion in a Src-FAK-dependent mechanism. We further 
identified Src as pivotal regulator of ECM remodelling via 
AKT/AP-1/MMP14 dependent pathway.
RESULTS
p63 expression is required for invasion of late 
passage E6/E7-HFK
To investigate the role of p63 in oro-pharyngeal 
squamous cell cancers (OPSCC) we utilised transformed 
HFKs expressing high risk HPV16 E6 and E7 genes, which 
we have previously shown to invade into the collagen-I 
plugs when cultured with retinoblastoma-depleted 
fibroblasts [20, 22]. Importantly, comparison of control 
(pBabe) HFK with early and late passage E6/E7-HFK 
indicates that invasion only occurs in late passage cells 
(>12 passages) (Fig. 1A and 1B), which is independent 
of cell proliferation as confirmed by similar BrdU 
incorporation in E6/E7-HFK (Supplementary Fig. 1A). 
Furthermore, mitomycin-C (inhibitor of cell proliferation)-
treated late passage cells demonstrated higher rate of cell 
migration (p <0.05) compared to the mitomycin-C-treated 
control and early passage E6/E7-HFK (Supplementary 
Fig. 2A and 2B) and indicated cell migration and not 
proliferation is essential for invasion.
Analysis of mRNA (Fig. 1C) and protein (Fig. 1D) 
levels of p63 indicated that p63 is upregulated in cells 
expressing E6/E7 genes and further increased in late 
passage population. Stable shRNA mediated depletion of 
p63 (Fig. 1E and 1F) in late passage E6/E7-HFK resulted 
in a significant decrease in the invasive incidents (Fig. 1G 
and 1H) suggesting that p63 expression is pivotal for 
invasion. In addition, transient knockdown of p63 isoforms 
by two different siRNA molecules (Fig. 2G) in late passage 
E6/E7-HFK impaired the cell migration suggesting that 
p63 is required for a migratory phenotype (Fig. 1I–1K).
p63 transcription factors modulate cell 
migration via Src-FAK signalling
Comparison of our previous genome wide ChIP-seq 
analyses of p63 function [9, 23] with microarray analyses 
of OPSCC [24] identified a number of p63 target genes 
whose expression like that of p63 (Fig. 2A) was elevated 
in both HPV positive, as measured by p16INK4A [p16+], and 
HPV negative [p16-]) oro-pharyngeal cancers compared 
to normal tissue [23]. In particular, we observed that 
both HPV-positive and -negative OPSCC tumours had 
elevated levels of Src and PTK2 (encodes focal adhesion 
kinase (FAK)) genes (Fig. 2A), which were associated 
with p63 binding sites detected by ChIP-seq in normal 
cells [23]. Importantly, only the Src expression correlated 
significantly with p63 levels in OPSCC tumours (Fig. 2B). 
In addition, the mRNA and protein levels of total Src 
were higher in late passage E6/E7-HFK compared to the 
other cell populations, albeit total FAK and paxillin levels 
were relatively unchanged (Fig. 2C and 2D). Src levels 
correlated with a marked increase in the activation of 
the Src-FAK complex as represented by elevated levels 
of pFAK-Y397 (auto-phosphorylation), pSrc-Y416 and 
pFAK-Y576/577 resulting in enhanced levels of pPaxillin-Y118 
which is a well-known target of the activated Src-FAK 
complex (Fig. 2D). In addition, late passage cells also 
appeared to have high rates of focal adhesion turnover, 
as suggested by increased cytoplasmic localisation of 
paxillin and pFAK-Y397 (Fig. 2E). In contrast, control HFK 
exhibited distinct peripheral localisation of paxillin, which 
coincided with faint peripheral localisation of pFAK-Y397. 
The early passage E6/E7-HFK exhibited an intermediary 
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Figure 1: p63 transcription factors drive cell migration and invasion in late passage human foreskin keratinocytes 
(HFK) expressing human papilloma virus (HPV)16 E6/E7 genes. A. H&E staining and immunofluorescence detection of BrdU 
uptake and nuclei (DAPI) on 3D-organotypic rafts established from normal HFK expressing pBabe (control), early passage and late passage 
HFK expressing E6/E7 genes cells seeded on retinoblastoma-depleted human foreskin fibroblast embedded collagen-I plugs. Invasive 
incidents are indicated by arrows. B. Quantification of number of invasive incidents across the rafts per cm. C. The relative mRNA and 
D. protein expression of total p63 and loading control β-actin in aforementioned cells. E. Relative mRNA and F. protein levels of total p63 
in late passage E6/E7-HFK after stable p63 (p63 shRNA) knockdown compared to its controls (scram shRNA). G. H&E staining of rafts 
established from late passage HFK expressing control and stable p63 knockdown. H. Quantification of number of invasive incidents per cm 
across the rafts. I. Relative mRNA levels of total p63 after transient knockdown by control and two different p63 siRNA molecules in late 
passage E6/E7-HFK. J. Representative phase contrast images of scratch wound assay, showing cell migration after 20 hr in these cells 
seeded on collagen-I coated plates. K. Quantification of migration represented as μm2/hr. Scale bars represent 100 μm. N = 3 independent 
experiments, mean ± SEM, **p < 0.01 compared to the respective controls, *p < 0.05 compared to the control, ††p < 0.01 compared to early 
passage E6/E7-HFK.
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phenotype with punctate membrane staining of paxillin 
(Fig. 2E).
To confirm the correlation between p63 and 
Src-FAK signalling axis, the transient knockdown p63 
isoforms by two different siRNA molecules in late passage 
E6/E7-HFK significantly reduced the mRNA and protein 
levels of PTK2 and Src and attenuated their activities as 
confirmed by depleted levels of pPaxillin-Y118 (Fig. 2F 
and 2G). These results indicate that p63 transcription 
factors regulate the expression and activities of FAK and 
Src signalling molecules, which may explain the impaired 
cell migration observed earlier after p63 knockdown.
Src-FAK signalling regulates cell migration 
and invasion
To confirm the role of Src-FAK signalling axis 
in enhanced migration of late passage E6/E7-HFK, we 
depleted Src or FAK expression in these cells by transient 
siRNA knockdown (Fig. 3A and 3B). As expected since 
Src activity is in part dependent on FAK activity, the FAK 
or Src knockdown reduced pSrc-Y416 and pPaxillin-Y118 
levels without altering the protein levels of total paxillin 
and p63 (Fig. 3B) and resulted in impaired cell migration 
compared to scrambled control (Fig. 3C and 3D) 
indicating that Src-FAK signalling enhanced cell migration 
through modulating the stability of focal adhesions. The 
reappearance of paxillin at cell periphery after FAK or Src 
knockdown confirms this notion and was similar to control 
cells (Supplementary Figure 3 vs Figure 2E). Since p63 
levels were unchanged in Src or FAK-depleted cells, these 
results indicate that p63 is not a transciptional target of 
Src-FAK signalling (Fig. 3B).
To ascertain the importance of FAK and Src in 
invasion and since we had used short acting siRNAs 
for the above experiments, we compared the effect 
of the specific inhibitors of FAK (PF573228) and Src 
(dasatinib) activities with control (DMSO), which 
resulted in significant decreases in the number of invasive 
incidents (Fig. 3E and 3F), with a minimal effect on cell 
proliferation (Supplementary Fig. 1B).
MMP14-mediated ECM remodelling is pivotal 
for invasion
We have previously reported elevated levels 
of MMP1 and MMP14 in tissue sections from oro-
pharyngeal cancer patients and also identified MMP14 as 
a direct p63 regulated gene in normal HFK [9, 22]. The 
microarray analysis of oro-pharyngeal cancers indicated 
increased levels of MMP1, but not MMP2, 9 and 14 in 
these tumours compared to normal tissue (Supplementary 
Fig. 4A) suggesting a potentially important role of MMPs 
in invasion.
The mRNA analysis indicated that levels of 
MMP1, 2 and 9 are upregulated (p < 0.05) in the late 
passage E6/E7-HFK compared to normal and early 
passage E6/E7-HFK (Fig. 4A), whereas, MMP14 levels 
were elevated (p < 0.05) even in early passage E6/E7-
HFK compared to control and remained elevated in the 
late passage population (Fig. 4A). These results were 
supported by a gradual increase in protein levels of 
MMP1 and 2 from non-invasive to the invasive population 
(Fig. 4B). Importantly, while protein levels of MMP14 
mirrored its mRNA expression, its enzymatic activity, as 
reported by the presence of cleaved MMP2 protein and 
extracellular MMP2-mediated digestion of gelatin, were 
elevated only in the invasive late passage E6/E7-HFK. 
This was also the case with MMP9 activity, which is 
potentially activated downstream of MMP2 (Fig. 4B).
Since MMP14 is well known to regulate the 
activities of MMP2 and MMP9 [25], we examined the 
effect of transient knockdown of MMP14 in late passage 
E6/E7-HFK (Fig. 4C and 4D). Depletion of MMP14 
expression caused a marginal reduction in mRNA 
and protein levels of MMP1 while having no effect on 
the mRNA/protein expression of MMP2 and MMP9. 
However, the extracellular activities of MMP2 and MMP9 
were dramatically reduced in the MMP14-knockdown 
cells (Fig. 4D). These results confirm the well known 
cascade of MMP activation and illustrate the importance 
of MMP14 [25]. Knockdown of MMP14, significantly 
attenuated the invasive incidents (Fig. 4E and 4F) without 
affecting cell proliferation (Supplementary Figure 1C), 
thus highlighting the significance of MMP14 expression 
in driving invasion.
Src-FAK signalling regulates MMP14-dependent 
ECM remodelling
Since specific inhibition of Src or FAK activities 
inhibited invasion, we next sought to determine their 
effect on the expression and activity of MMP14 since 
Src-signalling can regulate MMP levels [26]. Transient 
knockdown of FAK or Src (Fig. 5A) or specific inhibition 
of their activities appeared to deplete the mRNA and 
protein levels of MMP14 concomitant with reduction of 
the MMP2-mediated digestion of gelatin, thus confirming 
the attenuated MMP14 activity (Fig. 5B-5D). These 
results indicate that Src-FAK signalling may modulate 
the MMP14-mediated ECM remodelling by altering its 
expression and activity.
To further test this hypothesis we compared the 
effects of adenoviral-mediated wild type Src (Src-WT), 
constitutively active (Src-531) or kinase dead mutant 
(Src-KD) expression in early passage E6/E7-HFK, which 
do not invade. Our results indicate increased number 
of invasive incidents only in the Src-WT and Src-531 
expressing cells (Fig. 5E and 5F), which was independent of 
proliferation as confirmed by similar BrdU uptake between 
all the groups (Supplementary Fig. 1D). Furthermore, 
the Src-WT and Src-531 expressing cells show elevated 
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Figure 2: p63 transcription factors modulate Src-focal adhesion kinase (FAK) signalling. A. Microarray data of total 
p63, Src and PTK2/FAK mRNA levels in normal tissue and HPV-negative (p16-) and HPV-positive (p16+) oro-pharyngeal tumours. 
B. Correlation analysis of Src and PTK2/FAK against p63 in samples from (A). C. Relative mRNA levels of Src, PTK2/FAK and paxillin 
in human foreskin keratinocytes (HFK) expressing pBabe (control), early and late passage HFK expressing E6/E7 genes. D. Protein levels 
of total Src, FAK, paxillin, pSrc-Y416, pFAK-Y397, pFAK-Y576/577 and pPaxillin-Y118; E. cellular localisation (arrows) of total paxillin and 
pFAK-Y397 in aforementioned cells. F. Relative mRNA levels of PTK2/FAK and Src in p63 depleted cells and G. protein levels of total p63, 
Src, FAK, paxillin and pPaxillin-Y118 after transient knockdown by Scram (control) and two different p63 siRNA molecules in late passage 
E6/E7-HFK. β-actin served as loading control. Scale bars represent 50 μm. N = 3 independent experiments, mean ± SEM, ***p < 0.0001 
compared to normal, ##p < 0.01 compared to the control,  *p < 0.01 compared to the control, ††p < 0.01 compared to early passage E6/E7 
HFK, ns: not significant.
Oncotarget6www.impactjournals.com/oncotarget
A C
Scram siRNA   +      - -
FAK siRNA       - +      -
Src siRNA         - - +
Fo
ld
 d
iff
er
en
ce
 in
m
R
N
A
 le
ve
ls
Scram siRNA   +      - -
FAK siRNA       - +      -
Src siRNA         - - +
Fo
ld
 d
iff
er
en
ce
 in
m
R
N
A
 le
ve
ls
0
1
2
0
1
2
** **
PTK2/FAK Src 
S
cr
am
si
R
N
A
FA
K
si
R
N
A
S
rc
 
si
R
N
A
0 hr 20 hr
B
0.0
0.5
1.0
1.5
Fo
ld
 d
iff
er
en
ce
 in
 th
e 
ra
te
of
 c
el
l m
ig
ra
tio
n 
(µ
m
2 /h
r)
Scram siRNA     +        - -
FAK siRNA         - +       -
Src siRNA           - - +
*
*
DTotal FAK
Total Src
125 kDa
60 kDa
pFAK-Y397 125 kDa
pSrc-Y416 60 kDa
Scram siRNA        +         - -
FAK siRNA            - +        -
Src siRNA              - - +
β-actin 44 kDa
68 kDa
Total Paxillin 68 kDa
pPaxillin-Y118
Total p63 63-43 kDa
0
10
20
30
40
50
N
o.
 o
f i
va
si
on
s/
cm
DMSO                     +            - -
PF573228 (1 μM)    - +            -
Dasatinib (50 nM) - - +
** **
FE
DMSO PF573228 (1 μM) Dasatinib (50 nM)
B
rd
U
D
AP
I
H
 &
 E
 s
ta
in
in
g
Figure 3: Src-focal adhesion kinase (FAK) signalling regulates cell migration and invasion. A. Relative mRNA levels 
of PTK2/FAK and Src and, B. protein levels of total FAK, Src, paxillin, pSrc-Y416, pFAK-Y397, pPaxillin-Y118 and β-actin after transient 
knockdown by Scram (control), FAK and Src siRNA molecules in late passage human foreskin keratinocytes (HFK) expressing HPV16 E6/
E7 genes. C. Representative phase contrast images of scratch wound assay on collagen-I coated plates showing cell migration after transient 
knockdown with scram, FAK and Src siRNA in the late passage E6/E7-HFK, which was D. quantified and represented as μm2/hr. E. H&E 
staining and immunofluorescence detection of BrdU uptake and nuclei (DAPI) on 3D-organotypic rafts established from late passage E6/
E7-HFK seeded on retinoblastoma-depleted HFF embedded collagen-I plugs and treated with specific inhibitors of FAK (PF573228) 
and Src (dasatinib) activities. Rafts treated with DMSO served as control. Invasive incidents are indicated by arrows. F. Quantification 
of number of invasive incidents across the rafts per cm. Scale bars represents 100 μm. N = 3 independent experiments, mean ± SEM, 
**p < 0.01 compared to the respective controls, *p < 0.05 compared to the control.
Oncotarget7www.impactjournals.com/oncotarget
DCB
*†
pBabe HFK          +       - - +       - - +      - - +      - -
Early E6/E7 HFK  - +       - - +       - - +       - - +      -
Late E6/E7 HFK   - - +                - - +               - - +              - - +
Fo
ld
 d
iff
er
en
ce
 in
m
R
N
A
 le
ve
ls
0
1
2
3
4
5
0
2
4
6
8
0
2
4
6
8
MMP1 MMP2 MMP9 MMP14 
*† *† *
*
0
1
2
3
4
5
A
β-actin
MMP14
MMP1
proMMP2
MMP2
56 kDa
68 kDa
62 kDa
57 kDa
44 kDa
Extracellular 
MMP9 activity
88 kDa
Extracellular 
MMP2 activity
62 kDa
pBabe HFK            +       - -
Early E6/E7 HFK    - +        -
Late E6/E7 HFK     - - +
MMP1
proMMP2
MMP2
MMP14 56 kDa
68 kDa
62 kDa
57 kDa
β-actin 44 kDa
Extracellular 
MMP9 activity 88 kDa
Extracellular 
MMP2 activity 62 kDa
Scram siRNA        +        -
MMP14 siRNA       - +      
R
el
at
iv
e 
m
R
N
A
 le
ve
ls
0.0
0.5
1.0
1.5
MMP1 MMP2
MMP9 MMP14
Scram siRNA         +                     -
MMP14 siRNA       - +      
**
FE
Scram 
siRNA
MMP14 
siRNA
B
rd
U
D
AP
I
H
 &
 E
 s
ta
in
in
g
N
o.
 o
f i
nv
as
io
ns
/c
m
0
10
20
30
40
50
Scram siRNA     +          -
MMP14 siRNA    - +      
**
Figure 4: Matrix metalloproteinases (MMP)-mediated extra cellular matrix (ECM) remodelling is important during 
invasion. A. The relative mRNA levels of MMP1, 2, 9 and 14, B. protein expression and activities on gelatin zymographs of MMPs in 
human foreskin keratinocytes (HFK) expressing pBabe (control), early and late passage HFK expressing HPV16 E6/E7 genes. C. Relative 
mRNA levels of MMP1, 2, 9 and 14; and D. protein levels of MMP1, 2, 14 and extracellular activities of MMP2 and MMP9 after transient 
knockdown by Scram (control) or MMP14 siRNA molecules in the late passage E6/E7-HFK. E. H&E staining and immunofluorescence 
detection of BrdU uptake and nuclei (DAPI) on 3D-organotypic rafts established from aforementioned MMP14 knockdown cells. Invasive 
incidents are indicated by arrows. F. Quantification of number of invasive incidents across the rafts per cm. β-actin served as loading 
control. Scale bar represent 100 μm. N = 3 independent experiments, mean ± SEM, **p < 0.01 compared to the control, *p < 0.05 compared 
to the controls, †p < 0.05 compared to the early passage population.
Oncotarget8www.impactjournals.com/oncotarget
mRNA and protein levels of MMP14 alongside elevated 
levels of pSrc-Y416 and pFAK-Y576/577 which indicates the 
formation of activated Src-FAK complex and confirms 
that Src-mediated modulation of MMP14 expression and 
activity is pivotal for invasion (Fig. 5G and 5H). Depletion 
of Src or FAK did not affect p63 levels (Fig. 3B).
AKT activity modulates MMP14 levels via an 
AP-1-dependent mechanism
We have previously shown that AKT signalling 
regulates cell migration and expression of MMPs [21, 22], 
so we investigated if AKT maybe downstream of the 
Src-FAK complex. There were marginal and dramatic 
increases in the levels of pAKT-S473 in early and late 
passage E6/E7-HFK, respectively, compared to control, 
although the total AKT levels were similar between the 
groups (Figure 6A).
Since c-Jun, an AP-1 transcription factor, can be 
activated by AKT signalling pathway and it can regulate 
transcription of MMP14 [26, 27], we determined the 
expression and activity of c-Jun by analysing its total 
and serine73 phosphorylation level, respectively (Fig. 6A 
and 6B). This revealed that protein expression of c-Jun 
increased in both early and late passage E6/E7-HFK 
compared to the controls which was coupled with 
incremental increase in c-Jun activation as measured 
by p-c-Jun-S73 levels (Fig. 6A and 6B). Furthermore, 
the microarray analysis of OPSCC indicated increased 
levels of c-Jun in OPSCC compared to normal tissue 
(Supplementary Fig. 4B).
Therefore, to explore the link between AKT, 
c-Jun and MMP14, we compared effects of transient 
knockdown of total AKT in late passage E6/E7-HFK. 
Our results reveal significant decreases in the mRNA 
and protein levels of MMP14 and c-Jun following the 
knockdown of total AKT, which correlates with depletion 
of p-c-Jun73 (Fig. 6C and 6D). Since p63 levels were 
unchanged in AKT-depleted cells, these results indicate 
that AKT signalling may regulate MMP14 expression 
via AP-1-dependent mechanism. Indeed, the transient 
knockdown of c-Jun by two different siRNA molecules 
significantly reduced the mRNA and protein levels of 
MMP14 confirming this idea (Fig. 6E and 6F).
Src-FAK signalling modulates AP-1 via 
AKT pathway
Since the activation of the Src-FAK complex 
drives invasion in E6/E7-HFK in part by regulating the 
expression and activity of MMP14, we explored the 
connection between Src signalling and AKT-dependent 
AP-1 activity. Transient knockdown of total FAK or Src 
proteins in the invasive population dramatically reduced 
pAKT-S473 levels without altering the total AKT levels, 
therefore suggesting the Src-FAK-mediated activation 
of AKT signalling pathway (Fig. 6G). The reduction in 
c-Jun and p-c-Jun-S73 levels supported our previous data 
following the depletion of AKT (Fig. 6D) as their protein 
levels were also depleted after Src or FAK knockdown 
(Fig. 6G). These results indicate that Src-FAK signalling 
modulates AKT activity, which in turn regulates the 
activity of AP-1 transcription factors. Indeed, specific 
inhibition of FAK and Src activities in rafts established 
with the invasive population showed a pronounced 
reduction in the nuclear staining of p-c-Jun-S73 compared 
to vehicle treated control (Fig. 6H) and a subsequent 
reduction in invasion as previous shown (Fig. 3E and 3F). 
In addition, the cells expressing the constitutively active 
Src-531 molecule demonstrated increased protein levels 
of c-Jun and p-c-Jun-S73, which confirms the Src-mediated 
AP-1 activation (Fig. 6I).
p63 transcription factors modulate the activation 
of AKT/AP-1 signalling
Our earlier results have shown a reduction in 
invasion after p63 knockdown. Since AKT activation is 
pivotal for cell migration and invasion, the role of p63 
in activating AKT/AP-1 signalling was investigated. 
The transient knockdown of p63 by two different siRNA 
molecules in late passage E6/E7-HFK inhibited AKT 
activation as evident by diminished levels of pAKT-S473 
although the total AKT levels remained unchanged 
(Fig. 7A). The p63 knockdown also reduced the mRNA 
and protein levels of c-Jun and MMP14, thus indicating 
that these proteins are potential transcriptional targets of 
p63 (Fig. 7A and 7B). In addition, rafts establish with late 
passage E6/E7-HFK expressing stable p63 knockdown 
demonstrated a striking disappearance of p-c-Jun-S73 from 
the nuclei (Fig. 7C). Since cell proliferation remained 
similar in the p63-depleted cells (Supplementary Fig. 1E), 
invasion is due to both p63-mediated regulation of AP-1 
transcription and activity.
Since p63 and c-Jun regulate expression of many 
genes, further studies were designed to confirm the 
link between these transcription factors and to study 
their significance in relation to invasion. Transient 
knockdown of p63 or c-Jun (Fig. 8A) in late passage E6/
E7-HFK depleted the protein expression and activity of 
MMP14, and significantly reduced (p < 0.01) the invasive 
incidents on rafts (Fig. 8A-8C) with minimal effects on 
proliferation (Supplementary Fig. 1F). The same was true 
when we expressed the constitutively active Src molecule 
(Sc-531) in the p63 or c-Jun depleted late passage cells 
(Fig. 8A-8C), suggesting that p63 and c-Jun are required 
for invasion even in the presence of high levels of 
activated Src. Presumably this activity maintains levels 
of c-Jun and MMP14 for activation by Src-FAK/AKT. 
While the knockdown of p63 reduced c-Jun levels in the 
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late passage E6/E7-HFK, the reverse was not observed 
which confirms that c-Jun is a target of p63 isoforms 
(Fig. 8A). These results emphasize the role of p63 as an 
upstream regulator of Src-FAK/AP-1 signalling through 
transcriptional regulation and activation.
To further validate our in vitro results from primary 
HFK expressing E6/E7 genes, oro-pharyngeal cancer 
sections with known HPV status (as confirmed by two 
independent methods i.e. p16 staining and chromogenic 
in situ hybridisation (CISH)) were used to study the 
expression and localisation of p63, c-Jun, Src and MMP14. 
In normal epidermis adjacent to either HPV positive or 
negative tumours, intense nuclear localisation of p63 
was found only in the basal epithelial cells, with staining 
gradually fading in supra-basal epithelial population 
indicating differentiation and stratification of the normal 
epidermis (Fig. 8D). On the contrary, intense nuclear 
localisation of p63 was found throughout both HPV 
positive and negative tumours but was absent in the stromal 
cells. Similarly, the nuclear localisation of c-Jun appeared 
to be mainly in the basal and supra-basal regions of normal 
epithelium adjacent to both HPV positive and negative 
tissue and gradually disappeared due to stratification 
(Fig. 8D). However, pronounced nuclear localisation 
of c-Jun was observed in HPV positive and negative 
tumour areas and co-localised with p63 staining (Fig. 8D). 
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Figure 8: p63 regulates the Src/c-Jun/matrix metalloproteinases-14 (MMP14)-mediated extra cellular matrix (ECM) 
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MMP2 as read out of the MMP14 activity after knockdown with Scram (control), total p63 or c-Jun siRNA in late passage human foreskin 
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with cells from (A). C. Quantification of number of invasive incidents across the rafts per cm. D. Immunofluorescence detection and 
quantification (Q-score) of p63 and c-Jun in normal epithelium and tumour areas from HPV positive (+ve) and HPV negative (−ve) oro-
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Quantification of the level of increase in tumour tissue of 
both p63 and c-Jun is shown in Fig. 8D. In the stromal 
compartment, intense nuclear staining of c-Jun was only 
observed around the tumour areas of the sections, which 
may reflect the presence of enhanced paracrine signalling 
in the tumour microenvironment (Fig. 8D).
Oro-pharyngeal tumour sections were also stained 
for Src and MMP14. Weak cytoplasmic staining for Src 
and MMP14 was observed in the basal cells, but was not 
present in the stratified layers of normal epithelium in the 
HPV positive and negative tumour sections (Fig. 9A). On 
the contrary, intense cytoplasmic/membrane localisation of 
Src and MMP14 was observed in both HPV positive and 
negative tumour areas and this is quantified in Fig. 9A.
DISCUSSION
Here, we have shown for the first time that enhanced 
expression of Src induces invasion in E6/E7-HFK by 
(a) destabilising focal adhesions leading to potentiated 
cell migration; and (b) regulating expression and activity 
of MMP14, a pivotal proteinase, via AKT-dependent 
activation of AP-1 transcription factor c-Jun to promote 
ECM remodelling. This is all controlled by p63 regulating 
expression and/or activities of Src, FAK, AKT, c-Jun 
and MMP14.
Recent studies analysing RNA-seq and microarray 
data sets from HPV-positive and negative HNSCC have 
shown an increase in the levels of several transcription 
factors including p63 [28, 29]. We observed an increase in 
p63 expression after the expression of HPV16 E6 and E7 
genes in primary HFK. However, the induction of invasive 
incidents was observed only in rafts established with late 
passage populations of cells (>12 passages) suggesting 
that p63-mediated genomic alterations are required for 
the oncogenic transformation of epithelial cells. Our 
recent genome-wide analysis of p63 binding sites in HFK 
identified many p63 targets, which are involved in several 
pathophysiological processes including cell differentiation, 
motility, proliferation and ECM remodelling [8, 9].
The high levels of PTK2 and Src, known regulators 
of cell migration, alongside significant correlation 
between Src and p63 in OPSCC tumours, implicates Src 
signalling in the invasive of E6/E7-HFK. Although the 
mRNA and protein levels of FAK were similar in the non-
invasive and invasive population of HFK, its enhanced 
autophosphorylation was only observed in the invasive 
population and may be due to up-regulation and clustering 
of integrins, which are also known targets of p63 [8, 30]. 
In addition, p63 appears to regulate the expression of 
these tyrosine kinases as its depletion decreased levels 
and inhibited the formation of activated Src-FAK 
complex, thus impairing cell migration. These results go 
hand in hand with previous studies on FAK-null mice 
and Src knockdown cells, which also showed impaired 
migration in fibroblasts with peripheral reappearance of 
large focal contacts [10, 11, 17]. Specific inhibition of 
FAK (PF573228) and Src (dasatinib) activities impaired 
cell migration and invasion in organotypic cultures, with 
minimum affects on cell proliferation. Suppression of Src 
and FAK activities in breast cancer support our data and 
emphasise the Src-FAK-evoked cell migration is a major 
event in the biology of invasion [11].
The pronounced expression and activity of MMP1, 
2, 9 and 14 in oro-pharyngeal tumours and in the invasive 
E6/E7-HFK indicates that MMPs have a significant role in 
invasion. However, MMP14 is up-regulated in both HPV 
positive and negative tumours suggesting that this pathway 
is active in both types of cancer. Our knockdown studies 
in E6/E7-HFK confirm that the MMP14 activity is pivotal 
in driving invasion. This conclusion is of no surprise since 
MMP14 is known to activate gelatinases and also acts as a 
collagenase by digesting collagen-I, II and III to promote 
invasion [31]. In addition, MMP14 also plays a key role in 
potentiating cancer cell migration [32, 33]. These results 
are in agreement with recent findings, which indicate 
a poor 5-year survival rate in patients with increased 
MMP14 expression regardless of HPV status and make 
it a potential target since its selective inhibition blocked 
tumour growth, invasion and angiogenesis [34, 35].
Since specific inhibitors of Src and FAK were 
effective in reducing the number of invasions, we 
hypothesised that the increased Src-FAK activity may 
regulate expression and/or activity of MMP14. Gene 
knockdown or inhibition of FAK and Src activities 
attenuated the mRNA, protein levels and activity of 
MMP14. While MMP14 levels are similar in early 
and late passage E6/E7 expressing HFKs, only the latter 
invade since only the late passage cells have increase 
Src levels and activity. The importance of this is shown 
when adenovirus-mediated Src-WT or its constitutively 
active construct (Src-531) are expressed in early passage 
E6/E7-HFK, which do not normally invade, enhanced 
mRNA and protein expression of Src and MMP14 
with concomitant increase in their activities resulted in 
invasion on rafts. These results indicate that activated 
Src transcriptionally regulates MMP14 levels and also 
regulate its posttranslational modification and cytoplasmic 
trafficking, which are paramount to its activity. 
Recent studies in gastric carcinoma, breast cancer and 
chondrosarcoma cells exemplify the Src-FAK-mediated 
regulation of MMPs like MMP9 and MMP13 via 
activation of AP-1 transcription factors like c-Jun and 
c-Fos [36, 37]. In addition, active Src is known to directly 
phosphorylate MMP14 at Tyr573 and promote its mono-
ubiquitination at Lys581, which enhances its cytoplasmic 
trafficking and increases cellular migration and invasion 
through collagen-I matrix [38, 39]. In breast cancers, 
activated Src-FAK signalling enriches the cell surface 
with active MMP14 to promote metastasis, thus indicating 
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Figure 9: A. Immunofluorescence detection and quantification (Q-score) of Src and MMP14 in normal epithelium and 
tumour areas from HPV positive (+ve) and HPV negative (−ve) oro-pharyngeal squamous cell carcinomas. The nuclei 
are stained with DAPI. B. Schematic representation of the role of p63 proteins in regulating ECM remodelling, cell migration and invasion 
via Src/FAK/AKT/AP-1 signalling pathway. Scale bar represent 100 μm. N = 5 (HPV+ve) and 5 (HPV−ve) tumour sections, mean ± SEM, 
***p < 0.001 compared to the normal areas.
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posttranslational modification and membrane localisation 
are essential in MMP14-mediated invasion [40, 41].
To delineate the Src-FAK-dependent downstream 
signalling pathways, which may induce the expression 
of MMP14, we focused on c-Jun, since its expression 
and phosphorylation transcriptionally regulate MMPs 
and could be linked with tumour progression [36]. Since 
p-c-Jun-Ser73 levels were higher in the invasive population 
of E6/E7-HFK, it suggests an enhanced transcriptional 
activity of AP-1 could induce MMP14 expression. Indeed, 
ectopic levels of Src-WT or Src-531 in early passage 
E6/E7-HFK enhanced the p-c-Jun-Ser73 levels and up-
regulated the mRNA and protein expression of MMP14. 
In contrast, knockdown of c-Jun depleted the MMP14 
expression and abrogated the invasion on rafts. Previously, 
we had shown the AKT-mediated induction of MMP1 via 
ETS2-dependent mechanism [22]. Since ETS transcription 
factors regulate the expression and activity of c-Jun 
in melanoma cells, AKT signalling may also regulate 
expression and activity c-Jun [42]. Specific inhibition or 
depletion of AKT reduced the mRNA and protein levels 
of c-Jun and MMP14 and supported our hypothesis [43].
Our recent genome wide ChIP-seq analysis [9] 
and the results presented here, identify MMP14 as target 
of p63. Hence, we studied the role of p63 in regulating 
the Src/FAK/AKT/AP-1/MMP14 signalling pathway. 
Knockdown of p63 in the invasive population attenuated 
the mRNA and protein expression and/or activities of 
Src, FAK, AKT, c-Jun and MMP14 indicating that p63 
orchestrates the Src-mediated invasion. Since the ectopic 
levels of Src failed to induce expression/activity of 
MMP14 in cells depleted of either p63 or c-Jun, it appears 
that p63 and AP-1 transcription factors synergistically 
regulate the expression of MMP14 (Figure 9B) [44].
In summary, p63 drives invasion in E6/E7-HFK 
by modulating Src-FAK signalling which (a) triggers 
focal adhesion disassembly leading to cell migration, and 
(b) evokes expression and activity of MMP14 resulting 
in enhanced ECM remodelling. The combination of 
specific inhibitors of Src or FAK with MMP14 can be of 
therapeutic importance in a cancer that is overdue new 
treatments.
MATERIALS AND METHODS
Cell culture
Primary human foreskin keratinocytes (HFK) 
expressing either control vector (pBabe) or HPV16 
E6/E7 genes were cultured in Epilife medium (Life 
technologies, UK) to generate early (<10 passage) and 
late passage (>12 passage) cells [45]. The 3D-organotypic 
rafts were maintained in the E-medium for 14 days as 
previously described [46]. The late passage HFK cultured 
as monolayer or on the rafts were treated with either 
PF573228 (Tocris, UK) or dasatinib in their respective 
medium. Each organotypic raft was sliced in three parts 
(approximately 1–1.5 cm each) before embedding in 
paraffin and sectioned to generate three equal sized raft 
sections. These sections were used for H&E staining and 
immunofluorescence experiments. The invasive incidents 
were quantified using the three H&E stained sections from 
each raft and represented as invasive incidents/cm. This 
was carried out for three independent rafts generated form 
different HFKs cultures and statistics were performed 
using the number of invasive incidents/cm recorded from 
three independent experiments.
Site-directed mutagenesis and 
adenovirus generation
The human wild type (WT)-Src construct 
(pDONR223-Src) (Addgene) was used to 
generate constitutively active (Src-531) and kinase dead 
(Src-KD) constructs by introducing STOP codon after 
Tyr530 and replacing lysine by methionine (K298M), 
respectively, by QuikChange II-Site-directed 
Mutagenesis (Stratagene, UK) according to the 
manufacturer’s guidelines [47]. After mutations 
were confirmed by Bigdye terminator sequencing 
reaction (Life technologies, UK), 5 μg of individual 
constructs were recombined with the adenoviral pAd/
CMV/V5-DEST Gateway vector (Life technologies, 
UK) using Gateway-LR Clonase-II enzyme mix (Life 
technologies, UK) according to the manufacturer’s 
guidelines. All recombinant adenovirus were generated 
using 293T cells and were purified and titrated as 
previously described [48].
Retroviral constructs and stable knockdown
The stable knockdown by shRNA molecules in 
late passage E6/E7-HFK was achieved by retroviral 
transduction of pSuper-retro-neo constructs (scram, p63). 
The retroviral shRNA constructs were produced in 293T 
cells by using the phoenix system as previously described 
[22, 49].
Transient knockdown
50 nM of either non-specific (Scram) or specific 
siRNA targeting total FAK, Src, AKT, c-Jun, p63 and 
MMP14 (Figure Supplemental 5) were used to knockdown 
the target gene and protein expression in E6/E7-HFK as 
previously described [23].
Cell migration assay
The HFK seeded on collagen-I coated coverslips 
were treated with mitomycin C (2 μg/mL) for 2 hours 
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before introducing a scratch wound with a yellow pipette 
tip. Three bright field images were taken immediately 
after the scratch-wound was generated (time = 0 hr) and 
again in the same field after 20 hours. The rate of cell 
migration was calculated by the formula: (wound area 
at t = 0 hr - wound area at t = 20 hr)/20 for the three 
areas of each scratch wound and represented as μm2/hr. 
This was carried out in three independent experiments 
of scratch-wounds generated from three different HFKs 
cultures and statistics were performed using data from all 
the three independent experiments.
RNA extraction and quantitative real  
time-polymerase chain reaction (qRT-PCR)
RNA extraction was carried out using Trizol (Roche, 
US) according to the manufacturer’s instructions. For 
qRT-PCR, RNA was reverse transcribed to cDNA by 
transcriptor first strand cDNA synthesis kit (Roche, US) 
and the relative mRNA levels of genes were measured as 
previously described [23].
Western blotting
The protein levels of FAK, p63 (4A4), MMP1, 
MMP2, BrdU (Santacruz Biotech), Src, pFAK-Y395, 
MMP14 (Abcam), paxillin (BD biosciences), 
pPaxillin-Y118, pFAK-Y576/577, pSrc-Y496, pAKT-S493, total 
AKT, p-c-jun-S73, c-Jun (Cell Signaling) and β-actin 
(Sigma-aldrich) were detected in whole cell lysates by 
immunoblotting as previously described [50].
Immunofluorescence
To study the cellular localisation of proteins, 
monolayer of HFK was fixed (4% paraformaldehyde), 
permeabilised and exposed to primary and species-
specific secondary antibodies as previously described 
[50]. To study proliferation, the rafts were pulsed for 
16 hours with BrdU prior to sectioning. The antigens 
in the raft and oro-pharyngeal tumour sections were 
retrieved by heat induced epitope retrieval methods (tris 
buffer, citrate buffer) and the proteins were visualised 
through 20× magnification as previously described [49]. 
The intensities of staining were quantified by calculating 
the Q-score for proteins in normal and tumour areas. 
Q-score = Sum of (degree of intensity (-, +, ++, +++) × 
(% of tissue section))
Gelatin zymography
To measure the extracellular activities of MMP2 and 
9, the conditioned Epilife medium was normalised against 
the cell number and run on 7.5% SDS-PAGE containing 
0.1% gelatin. The enzyme activities were observed 
by MMP-mediated digestion of gelatin as previously 
described [51].
Cell viability
Small aliquots of cell suspension were mixed with 
equal volume of 0.1% trypan blue for 5 minutes. The 
mixture was pipetted on haemacytometer, and percentage 
of viable cells was calculated by counting unstained cells 
per 100 cells.
Microarray analysis
The HNSCC microarray analysis was carried out 
as previously described [23]. Briefly, differential gene 
expression analysis of Robust Multi-array Average 
normalized data [24] was used to compare HPV-positive 
and -negative tumours with normal tissue using a three-
way ANOVA model incorporating tumour/normal, site and 
HPV status.
Statistics
Results were presented as mean ± SEM. Statistical 
analysis was performed by using IBM SPSS 20.0 software 
and comparing the mean by student’s t-test and one-way 
analysis of variance (ANOVA) followed by Dunnet’s post 
hoc analysis. The P < 0.05 was considered to be significant 
in all the experiment.
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